BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 22085233)

  • 21. Increased non-prostate cancer death risk in clinically diagnosed prostate cancer.
    van Leeuwen PJ; Otto SJ; Kranse R; Roobol MJ; Bul M; Zhu X; de Koning H; Schröder FH
    BJU Int; 2012 Jul; 110(2):188-94. PubMed ID: 22288823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone.
    Parekh A; Chen MH; Hoffman KE; Choueiri TK; Hu JC; Bennett CL; Kattan MW; Sartor O; Stein K; Graham PL; D'Amico AV; Nguyen PL
    Urology; 2013 Jan; 81(1):130-4. PubMed ID: 23273077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE.
    Elliott SP; Meng MV; Elkin EP; McAninch JW; Duchane J; Carroll PR;
    J Urol; 2007 Aug; 178(2):529-34; discussion 534. PubMed ID: 17570425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Information needs of men on androgen deprivation therapy.
    Soeyonggo T; Warde P; Fleshner N; Timilshina N; Alibhai SM
    BJU Int; 2012 May; 109(10):1503-9. PubMed ID: 21883845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry.
    Punnen S; Cowan JE; Chan JM; Carroll PR; Cooperberg MR
    Eur Urol; 2015 Oct; 68(4):600-8. PubMed ID: 25242555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy.
    Chen RC; Sadetsky N; Chen MH; Carroll PR; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):36-9. PubMed ID: 19233568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
    Nieder AM; Porter MP; Soloway MS
    J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy.
    Dosoretz AM; Chen MH; Salenius SA; Ross RH; Dosoretz DE; Katin MJ; Mantz C; Nakfoor BM; D'Amico AV
    Cancer; 2010 Feb; 116(4):837-42. PubMed ID: 20052734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke.
    Hayes JH; Chen MH; Moran BJ; Braccioforte MH; Dosoretz DE; Salenius S; Katin MJ; Ross R; Choueiri TK; D'Amico AV
    BJU Int; 2010 Oct; 106(7):979-85. PubMed ID: 20230380
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer.
    Efstathiou JA; Skowronski RY; Coen JJ; Grocela JA; Hirsch AE; Zietman AL
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1302-8. PubMed ID: 18262732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease.
    Arvold ND; Chen MH; Moul JW; Moran BJ; Dosoretz DE; Bañez LL; Katin MJ; Braccioforte MH; D'Amico AV
    J Urol; 2011 Jul; 186(1):91-6. PubMed ID: 21571341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
    Tsai HK; Chen MH; McLeod DG; Carroll PR; Richie JP; D'Amico AV
    Cancer; 2006 Dec; 107(11):2597-603. PubMed ID: 17039498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of secondary treatment following biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database.
    Moreira DM; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
    BJU Int; 2010 Jan; 105(1):28-33. PubMed ID: 19522861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer.
    Sartor O; McLeod DG; Halabi S; Schellhammer PF; Scardino PT; D'Amico AV; Bennett C; Wei JT;
    Urology; 2010 Mar; 75(3):623-9. PubMed ID: 19589569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study.
    Potosky AL; Davis WW; Hoffman RM; Stanford JL; Stephenson RA; Penson DF; Harlan LC
    J Natl Cancer Inst; 2004 Sep; 96(18):1358-67. PubMed ID: 15367568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
    Palma D; Tyldesley S; Pickles T;
    Cancer; 2008 May; 112(9):1941-8. PubMed ID: 18338814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patients' perceptions of quality of life after treatment for early prostate cancer.
    Clark JA; Inui TS; Silliman RA; Bokhour BG; Krasnow SH; Robinson RA; Spaulding M; Talcott JA
    J Clin Oncol; 2003 Oct; 21(20):3777-84. PubMed ID: 14551296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.
    Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1439-44. PubMed ID: 19540066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.
    Harlan SR; Cooperberg MR; Elkin E; Lubeck DP; Meng M; Mehta SS; Carroll PR
    J Urol; 2003 Nov; 170(5):1804-7. PubMed ID: 14532780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.